Lessons from COVID-19 in Clinical Neurology

Park, Jin‐Woo; Kim, Byung Jo

doi:10.3988/jcn.2022.18.1.1

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interaction between the viral spike protein on the virion surface and angiotensin-converting enzyme 2, which triggers the virus entering host cells, is likely to be involved in the CV manifestations of COVID-19. 34 38 A hypercoagulable state with elevated fibrinogen and factor VIII levels, 39 hyperactivation of platelets, and direct endothelial or vascular injury caused by SARS-CoV-2 infection might also increase the risk of thrombus formation and CV events, especially among critically ill patients. 40 41 Finally, genetic factors may contribute to the susceptibility and response to viral infection.…”

Section: The Fact: Reduction In CV Admissionsmentioning

confidence: 99%

Cerebro-/Cardiovascular Collateral Damage During the COVID-19 Pandemic: Fact or Fiction?

et al. 2023

View full text Add to dashboard Cite

Numerous observational studies have identified a decline in cerebro-/cardiovascular (CV) admissions during the initial phase of the COVID-19 pandemic. Recent studies and meta-analyses indicated that the overall decrease was smaller than that found in initial studies during the first months of 2020. Two years later we still do not have clear evidence about the potential causes and impacts of the reduction of CV hospitalizations during the COVID-19 pandemic. It has becoming increasingly evident that collateral damage (i.e., incidental damage to the public and patients) from the COVID-19 outbreak is the main underlying cause that at least somewhat reflects the effects of imposed measures such as social distancing and self-isolation. However, a smaller true decline in CV events in the community due to a lack of triggers associated with such acute syndromes cannot be excluded. There is currently indirect epidemiological evidence about the immediate impact that the collateral damage had on excess mortality, but possible late consequences including a rebound increase in CV events are yet to be observed. In the present narrative review, we present the reporting milestones in the literature of the rates of CV admissions and collateral damage during the last 2 years, and discuss all possible factors contributing to the decline in CV hospitalizations during the COVID-19 pandemic. Healthcare systems need to be prepared so that they can cope with the increased hospitalization rates for CV events in the near future.

show abstract